ebola virus

EBOV-IN-1 是一种针对埃博拉病毒(EBOV)的金刚烷二肽哌嗪抑制剂。它通过与Niemann-Pick C1 (NPC1)相互作用，阻断该蛋白与启动病毒穿透宿主细胞的EBOV糖蛋白(GP)的结合，进而抑制EBOV的感染。EBOV-IN-1对假型EBOV感染具有IC50为13 nM的抑制效力。

3-​Phenyl-​N-​[1-​(phenylmethyl)​-​4-​piperidinyl]​-tricyclo[3.3.1.13,​7]​decane-​1-​carboxamide 具有抗埃博拉病毒的抗病毒活性靶向表面暴露的糖蛋白并抑制病毒进入宿主细胞。 Vero 细胞的体外研究表明，该化合物抑制病毒复制，EC50 为 0.38 μM。

N-(1-benzyl-4-piperidyl)adamantane-1-carboxamide 通过与表面糖蛋白结合抑制埃博拉病毒进入宿主细胞，该化合物抑制埃博拉病毒，EC50 为 3.9 μM。

FGI-106 is a potent, broad-spectrum inhibitor demonstrating activity against various viruses, including Ebola, Rift Valley Fever, and Dengue Fever, exhibiting EC50 values of 100 nM, 800 nM, and 400-900 nM, respectively. Furthermore, it effectively inhibits non-hemorrhagic fever viruses such as HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively.

FGI-106 tetrahydrochloride 对多种病毒具有抑制活性，有抗埃博拉病毒，裂谷病毒和登革热病毒的 EC50分别为 100 nM，800 nM 和 400-900 nM，抑制非失血性发热病毒HCV 和HIV-1的EC50分别为 200 nM 和 150 nM 。

matrix protein (3-15) [Zaire ebolavirus] is a peptide of the structural proteins linking the viral envelope with the zaire ebolavirus core. Ebola virus (EBOV) is a member of the family Filoviridae in the order Mononegavirales. It is the causative agent of

U18666A 是一种细胞渗透性药物，是一种胆固醇合成和转运抑制剂，抑制埃博拉病毒，登革热病毒和人类丙型肝炎病毒的复制。

IHVR-19029 is an effective endoplasmic reticulum (ER) α-glucosidases I and II inhibitor (IC50: 0.48 μM for ER a-glucosidase I). IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Ebola virus, Dengue virus, and Rift

Pyronaridine tetraphosphate 是一种具有口服活性的、含甘露醇的DNA 拓扑异构酶 2 的抑制剂和红细胞裂殖杀灭剂，具有抗疟活性和抗肿瘤活性。Pyronaridine tetraphosphate 可治疗 P. falciparum 和 Echinococcus granulosus感染，可减轻埃博拉病毒传播。

Antiviralagent 59（compound 58）是一种广谱丝状病毒抑制剂，具有选择性和类药物特性。它对埃博拉病毒（EBOV）、苏丹病毒（SUDV）和马尔堡病毒（MARV）这些具有复制能力的病毒展示了低脱靶活性和有效的抑制作用。

EBOV-IN-10 为一种口服活性埃博拉病毒 (EBOV) 抑制剂，其 EC50 值达到 0.19 μM。

BIBX 1382 Dihydrochloride prevents Lassa and Ebola virus glycoprotein-dependent cells from entering the body. It can be used as a tool to understand conserved virus-host interactions and suggests that host cell kinases may be targets for broad-spectrum th

Anti-virus agent 1 (compound 4i), a phosphoramidate prodrug of GS-5734, exhibits potent antiviral efficacy. It is primarily utilized in the study of coronavirus and Ebola virus (EBOV).

Cephaeline hydrochloride 是 Indian Ipecac 中的一种酚类生物碱。它有效抑制病毒 ZIKV 和 EBOV 感染。

As-358 对埃博拉病毒 (IC50 = 47.5 μM) 和马尔堡病毒 (IC50 = 3.7 μM) 具有抑制作用。

As-358 (hydrochloride) 显示出良好的体内安全性，并且抑制埃博拉病毒和马尔堡病毒，IC50值分别为 9.1 μM 和 18.1 μM。

EBOV-GP-IN-1 (Compound 28) 是一种有效的 Ebola 进入抑制剂，能够作用于埃博拉病毒包膜糖蛋白（EBOV-GP）(IC50: 0.05 μM)。

EBOV-IN-C31 is a novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties.

Remdesivir, also known as GS-5734, is a prodrug form of the antiviral nucleoside analog GS-44152. Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. Efficacy of remdesivir against Ebola virus has been demonstrated. Remdesivir inhibits SARS-CoV-2 replication, reduces viral load, and exerts protective effects in SARS-CoV-2 infected animals. Remdesivir also reduces the pathological process, alleviates mild symptoms, and improves pulmonary lesions in SARS-CoV-2-infecetd animals. Remdesivir has been used as a compassionate drug for treating COVID-19 patients. *******WARNING****** Our product remdesivir is a pure chemical solid powder which is only for laboratory research use, NOT FOR HUMAN OR PATIENT USE

CLR01 is a molecular tweezer. CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy. CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS. CLR01 inhibits Ebola and Zika virus infection. CLR01 Stabilizes a Disordered Protein-Protein Interface. CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.

Thiocarbazate, also known as CID16725315, is an inhibitor of human cathepsin L. Inhibition of cathepsin L thus holds promise for therapeutic intervention for both SARS-CoV and Ebola virus infection. With respect to the development of antiviral agents, inhibitors of human cathepsin L are not subject to resistance because of rapid mutations of the viral genome. Cathepsin L is therefore an attractive target for drug development.

Oxocarbazate, also known as CID23631927, is an inhibitor of human cathepsin L. In the cathepsin L inhibition assay, The oxocarbazate caused a time-dependent 17-fold drop in IC50 from 6.9 nM (no preincubation) to 0.4 nM (4-h preincubation). Slowly reversible inhibition was demonstrated in a dilution assay. CID23631927 demonstrate activity in blocking both SARS-CoV (IC50 = 273 nM) and Ebola virus (IC50 = 193 nM) entry into human embryonic. CID 23631927 was a subnanomolar, slow-binding, reversible inhibitor of human cathepsin L that blocked SARS-CoV and Ebola pseudotype virus entry in human cells. Inhibition of cathepsin L thus holds promise for therapeutic intervention for both SARS-CoV and Ebola virus infection.

Eritoran是一种Toll样受体4 (TLR4) 拮抗剂，能够保护小鼠免受包括埃博拉病毒(EBOV)、马尔堡病毒(MARV)在内的致命流感病毒感染。该化合物通过降低粒细胞增多水平，可能有助于减轻“细胞因子风暴”的严重程度，抑制丝状病毒感染的发病机制。

Larcaviximab (c4G7-N) 是一种IgG1kappa 抗Ebola virus 糖蛋白嵌合单克隆抗体。